#United States #Brentwood #CONTRAVE #Currax Pharmaceuticals #MYSIMBA

Currax Pharmaceuticals Reports Impressive 2024 Performance

Currax Pharmaceuticals LLC, a prominent player in the specialty pharmaceutical industry, has announced outstanding financial and operational results for the year 2024. The company, known for its flagship product CONTRAVE®—the leading branded oral medication for weight loss—has achieved over 50% revenue growth for the second consecutive year. This remarkable performance is driven primarily by soaring patient demand and enhanced access to CONTRAVE and MYSIMBA in the United States and beyond.

With global sales surpassing 2.2 million units, Currax has extended the availability of its core products to over 50 countries. This expansion not only reaffirms the company's commitment to long-term growth but also indicates a surge in the popularity of its products. Consequently, Currax is poised to bolster its U.S. sales team by approximately 25% in the first quarter of 2025, a strategic move to capture an even larger share of the booming market for anti-obesity medications.

An additional key highlight of 2024 was the successful completion and subsequent approval of a second manufacturing facility dedicated to the production of CONTRAVE. This new site has doubled Currax's manufacturing capabilities, thereby reinforcing the stability of supply and ensuring that the company can meet the increasing global demand for its products amid ongoing supply chain challenges faced by competitors.

In a significant step forward, Currax also launched the INFORMUS Cardiovascular Outcomes Trial (NB-CVOT3) at the beginning of 2024. With over 2,600 of the anticipated 8,600 patients already enrolled, the trial aims to explore the cardiovascular safety of CONTRAVE in a diverse patient population. Additionally, a comprehensive Health Outcomes Analysis (HOA) was completed, showcasing positive results that were well received at the recent International Society for Pharmacoepidemiology (ISPE) conference.

Currax has further enhanced its marketing efforts through a series of initiatives aimed at raising awareness and promoting engagement with potential customers. Notably, the unbranded campaign dubbed "Quiet the Food Noise" launched in September 2024, was accompanied by a video series that generated considerable media attention. Major outlets such as CNBC and Bloomberg covered Currax's growing influence within the pharmaceutical landscape. The launch of the "Cravings Don't Own Me" television advertisement toward the end of the year also received positive initial feedback, marking another crucial stride in Currax's omnichannel marketing approach.

As the obesity treatment market continues to expand, Currax stands at the forefront of this trend, with its proprietary treatment CONTRAVE leading the pack as the only drug in the Reward System Regulator (RSR) class. According to George Hampton, the President and CEO of Currax, the company attributes its success to its patient-focused strategy and is poised to further integrate these efforts as it navigates the expected growth of the anti-obesity medications market—all while maintaining strong profitability and cash availability for reinvestments.

With the dedication to not only combat obesity but also the lifestyle challenges associated with it, Currax Pharmaceuticals envisions a bright future. Their ongoing commitment to innovation, patient care, and market responsiveness positions them as pivotal players in addressing critical health challenges facing contemporary society.